An advisory committee for the Food and Drug Administration has suggested easing regulations on six peptides. This recommendation comes despite concerns from FDA scientists over insufficient data supporting the peptides’ safety and effectiveness. These compounds are promoted for various benefits, including faster healing, youthful skin, and increased lifespan. However, there is a lack of concrete evidence to confirm these claims.
The meeting ended with the suggestion to allow compounding of two additional peptides that remain unproven. This decision, made during a two-day session, sparks questions about the FDA’s commitment to maintaining strict controls to prevent untested drugs from reaching the public.
FDA Permits Zyn Nicotine Pouches as Lower Risk Alternative to Cigarettes 
Salad and Go Closes Locations Amid Cyclospora Outbreak Concerns 
Foodborne Pathogens Pose Growing Threats in the U.S. 
RFK Jr.’s Evolving Stance on Vaccines Amid Measles Outbreaks 
Transforming Healthcare with AI: A Human-Centric Approach 
Polyethylene Exposure Linked to Fatty Liver Disease